163 related articles for article (PubMed ID: 18793033)
21. The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease.
Brugts JJ; de Maat MP; Boersma E; Witteman JC; van Duijn C; Uitterlinden AG; Bertrand M; Remme W; Fox K; Ferrari R; Danser AH; Simoons ML;
Cardiovasc Drugs Ther; 2009 Apr; 23(2):171-81. PubMed ID: 19082699
[TBL] [Abstract][Full Text] [Related]
22. EUROPA substudies, confirmation of pathophysiological concepts. European trial on reduction of cardiac events with perindopril in stable coronary artery disease.
Simoons ML; Vos J; de Feyter PJ; Bots ML; Remme WJ; Grobbee DE; Kluft C; de Maat MP; Fox KM; Deckers JW
Eur Heart J; 1998 Sep; 19 Suppl J():J56-60. PubMed ID: 9796842
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of perindopril in reducing risk of cardiac events in patients with revascularized coronary artery disease.
Fox KM; Bertrand ME; Remme WJ; Ferrari R; Simoons ML; Deckers JW;
Am Heart J; 2007 Apr; 153(4):629-35. PubMed ID: 17383303
[TBL] [Abstract][Full Text] [Related]
24. ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial.
Bots ML; Remme WJ; Lüscher TF; Fox KM; Bertrand M; Ferrari R; Simoons ML; Grobbee DE;
Cardiovasc Drugs Ther; 2007 Aug; 21(4):269-79. PubMed ID: 17657599
[TBL] [Abstract][Full Text] [Related]
25. [Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI].
Ferrari R; Papa K; Bernocchi P; Gimbatti OJ; Golcea SS; Bettini A; Ceconi C
Ital Heart J; 2005 Nov; 6 Suppl 7():24S-32S. PubMed ID: 16485514
[TBL] [Abstract][Full Text] [Related]
26. Tailored therapy of ACE inhibitors in stable coronary artery disease: pharmacogenetic profiling of treatment benefit.
Brugts JJ; Boersma E; Simoons ML
Pharmacogenomics; 2010 Aug; 11(8):1115-26. PubMed ID: 20712529
[TBL] [Abstract][Full Text] [Related]
27. Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study.
Bertrand ME; Ferrari R; Remme WJ; Simoons ML; Deckers JW; Fox KM;
Am Heart J; 2010 May; 159(5):795-802. PubMed ID: 20435188
[TBL] [Abstract][Full Text] [Related]
28. PERTINENT--perindopril-thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub-study of the EUROPA study.
Scientific Committee of the PERTINENT Sub-Study, EUROPA-PERTINENT Investigators
Cardiovasc Drugs Ther; 2003 Jan; 17(1):83-91. PubMed ID: 12843690
[TBL] [Abstract][Full Text] [Related]
29. PERSUADE...(a EUROPA sub-study)...results: perindopril protects diabetic patients with coronary disease from cardiovascular death and heart attacks.
Cardiovasc J S Afr; 2004; 15(3):146. PubMed ID: 15356914
[No Abstract] [Full Text] [Related]
30. The Treatment Effect of an ACE-Inhibitor Based Regimen with Perindopril in Relation to Beta-Blocker use in 29,463 Patients with Vascular Disease: a Combined Analysis of Individual Data of ADVANCE, EUROPA and PROGRESS Trials.
Brugts JJ; Bertrand M; Remme W; Ferrari R; Fox K; MacMahon S; Chalmers J; Simoons ML; Boersma E
Cardiovasc Drugs Ther; 2017 Aug; 31(4):391-400. PubMed ID: 28856537
[TBL] [Abstract][Full Text] [Related]
31. The EUROPA trial.
Stoschitzky K
Lancet; 2003 Dec; 362(9399):1935-6; author reply 1936-7. PubMed ID: 14667757
[No Abstract] [Full Text] [Related]
32. Prediction of absolute risk reduction of cardiovascular events with perindopril for individual patients with stable coronary artery disease - results from EUROPA.
van der Leeuw J; Oemrawsingh RM; van der Graaf Y; Brugts JJ; Deckers JW; Bertrand M; Fox K; Ferrari R; Remme WJ; Simoons ML; Boersma E; Visseren FL
Int J Cardiol; 2015 Mar; 182():194-9. PubMed ID: 25577762
[TBL] [Abstract][Full Text] [Related]
33. Pleiotropic effects of angiotensin-converting enzyme inhibitors in normotensive patients with coronary artery disease.
Krysiak R; Okopień B
Pharmacol Rep; 2008; 60(4):514-23. PubMed ID: 18799820
[TBL] [Abstract][Full Text] [Related]
34. Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial.
Ferrari R; Bertrand ME; Remme WJ; Simoons ML; Deckers JW; Fox KM
Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1037-46. PubMed ID: 18035919
[TBL] [Abstract][Full Text] [Related]
35. Evidence for benefits of perindopril in hypertension and its complications.
Laurent S
Am J Hypertens; 2005 Sep; 18(9 Pt 2):155S-162S. PubMed ID: 16125052
[TBL] [Abstract][Full Text] [Related]
36. The cost-effectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: a Swedish sub-study to the HOPE study.
Björholt I; Andersson FL; Kahan T; Ostergren J
J Intern Med; 2002 Jun; 251(6):508-17. PubMed ID: 12028506
[TBL] [Abstract][Full Text] [Related]
37. The EUROPA trial.
Kwaku M; Burman KD; Becker KL; Mannan M
Lancet; 2003 Dec; 362(9399):1935; author reply 1936-7. PubMed ID: 14667758
[No Abstract] [Full Text] [Related]
38. Combine EUROPA and HOPE.
Fuller JA
Lancet; 2003 Dec; 362(9399):1937. PubMed ID: 14667761
[No Abstract] [Full Text] [Related]
39. Cost-effectiveness of lowering blood pressure with a fixed combination of perindopril and indapamide in type 2 diabetes mellitus: an ADVANCE trial-based analysis.
Glasziou PP; Clarke P; Alexander J; Rajmokan M; Beller E; Woodward M; Chalmers J; Poulter N; Patel A
Med J Aust; 2010 Sep; 193(6):320-4. PubMed ID: 20854235
[TBL] [Abstract][Full Text] [Related]
40. The EUROPA trial.
Boos C
Lancet; 2003 Dec; 362(9399):1935; author reply 1936-7. PubMed ID: 14667756
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
